Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
PACMAN-Hu19 trial of locally produced CD19-targeted CAR T-cell therapy
NL-OMON60532Phase 2Not yet recruiting
- Sponsor
- Princess Máxima Center for Pediatric Oncology
- Start
- Jan 2026
- Modality
- CAR-T Cells → Engineered T Cells → Adoptive Cell Transfer → Cell Therapies, Gene Therapies
- Countries
- 1
01
Overview
Phase 2, open-label trial of MB-HUCART19.1 in acute lymphoblastic leukemia (ALL) and mature B-cell lymphoma (2 cohorts), sponsored by Princess Máxima Center for Pediatric Oncology. Primary endpoint: Dose-limiting toxicity incidence and RP2D determination. Planned start Jan 2026; status: not yet recruiting.
02
Drugs
MB-HUCART19.1
03
Conditions
acute lymphoblastic leukemia (ALL)mature B-cell lymphoma
Beyond the preview
Go deeper on NL-OMON60532.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NL-OMON60532.